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Background: While mental comorbidity is considered common in multiple sclerosis (MS), its impact is poorly
defined; methods are needed to support studies of mental comorbidity. We validated and applied administrative
case definitions for any mental comorbidities in MS.
Methods: Using administrative health data we identified persons with MS and a matched general population
cohort. Administrative case definitions for any mental comorbidity, any mood disorder, depression, anxiety, bipolar
disorder and schizophrenia were developed and validated against medical records using a a kappa statistic (k).
Using these definitions we estimated the prevalence of these comorbidities in the study populations.
Results: Compared to medical records, administrative definitions showed moderate agreement for any mental
comorbidity, mood disorders and depression (all k ≥ 0.49), fair agreement for anxiety (k = 0.23) and bipolar disorder
(k = 0.30), and near perfect agreement for schizophrenia (k = 1.0). The age-standardized prevalence of all mental
comorbidities was higher in the MS than in the general populations: depression (31.7% vs. 20.5%), anxiety (35.6% vs.
29.6%), and bipolar disorder (5.83% vs. 3.45%), except for schizophrenia (0.93% vs. 0.93%).
Conclusions: Administrative data are a valid means of surveillance of mental comorbidity in MS. The prevalence of
mental comorbidities, except schizophrenia, is increased in MS compared to the general population.
Keywords: Multiple sclerosis, Administrative data, Validation, Prevalence, Depression, Anxiety, Bipolar disorder,
SchizophreniaBackground
Although depression and anxiety are considered com-
mon in MS [1,2], population-based prevalence estimates
for these conditions are rare. Even fewer prevalence esti-
mates exist for bipolar disorder and schizophrenia in the
MS population, and they vary widely [3,4]. The paucity
of population-based studies of mental comorbidity may
reflect the challenges of conducting such studies. How-
ever, such studies are needed given the impact of mental* Correspondence: rmarrie@hsc.mb.ca
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reproduction in any medium, provided the orcomorbidity in MS, including lower quality of life and
reduced adherence to treatment [5,6]; and to minimize
the biases from using clinic-based samples.
Studies of mental comorbidity could potentially use one
of several data sources including medical records review,
self-report, interviews, or administrative data. Administra-
tive data are population-based in publicly funded health
systems such as Canada and are cost-effective and access-
ible [7]. Such data are useful for assessing the burden of
disease at the population level, including health services
use and costs [8]. Mental comorbidities can be assessed in
clinical samples using structured diagnostic interviews
such as the Composite International Diagnostic Interview
(CIDI) although these are time consuming and dependLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have the advantage that they are recorded during an epi-
sode and need not be recalled later. Administrative data,
however, are collected for health system management and
are often inadequately validated [7,10]. Indeed, few pub-
lished case definitions for mental comorbidity have been
validated, and efforts to develop and validate case defini-
tions for depression have identified poor concordance
with the CIDI Short Form [11], and difficulties distin-
guishing depression from anxiety [12].
We aimed to validate administrative case definitions for
several mental comorbidities in MS, and to describe their
prevalence among persons with MS versus a matched co-
hort from the general population. We hypothesized that
the prevalence of depression, anxiety, bipolar disorder and
schizophrenia would be higher in the MS population than
in the general population.
Methods
Administrative data
We conducted this study in Manitoba, Canada, using
anonymized administrative data obtained from Manitoba
Health (MH) which provides health care services for more
than 98% of Manitoba residents [13]. Since 1984, MH has
maintained computerized records of health services claims,
which can be linked using a unique personal health identifi-
cation number (PHIN) identifying the person who received
the service. Physician claims include the PHIN, service
date, and three-digit International Classification of Disease
(ICD)-9-CM code for one physician-assigned diagnosis.
Hospitalization records include the PHIN, admission and
discharge dates, and up to 16 discharge diagnoses. Before
2004, diagnoses were listed using five-digit ICD-9-CM
codes and since 2004 they have been listed using ICD-10-
CA codes. Since 1996, the Drug Programs Information
Network captures outpatient prescription drug dispensa-
tions including date, drug name, and drug identification
number for Manitoba residents, regardless of payer. The
population registry is updated when an individual migrates
into or out of Manitoba, or dies.
Study populations and validation cohort
Using data from 1984 to 2006, we identified all Manitobans
with MS using a previously validated administrative case
definition [14]. We identified up to 5 controls from the
general population for each MS case, matched on sex, year
of birth and region of residence (postal code), and exclud-
ing anyone with an ICD9/10-code for any demyelinating
disease as previously described [14]. As described in detail
previously, the medical records of 430 persons with MS
were reviewed by a trained abstractor using a standardized
data collection form [14,15]. Using each participant’s
PHIN, these clinical data were linked with the administra-
tive databases.Administrative case definitions
We aimed to develop case definitions for depression,
anxiety, bipolar disorder and schizophrenia using estab-
lished approaches [16]. Developing case definitions for
mental comorbidity raised challenges. Although hospital
claims provide 5-digit ICD codes, physician claims in
Manitoba have only three digits, reducing the specificity
of coding. For example, at the 3-digit level, the same
code (296) describes bipolar I disorder, most recent epi-
sodic manic (296.4) and major depressive disorder recur-
rent episode (296.3). Therefore, we initially created an
‘omnibus’ definition for mental comorbidity to capture
persons with any of the mental comorbidities of interest,
followed by an ‘any mood or anxiety disorders’ definition
which captured depressive disorders, anxiety disorders
and bipolar disorder. Finally, we developed case defini-
tions for individual mental comorbidities. We identified
ICD-9/10 codes for the individual comorbidities and the
combination definitions (Additional file 1: Table S1).
While incorporating prescription claims might improve
specificity of the case definitions, many medications used
for mental comorbidities are used off-label for other pur-
poses, particularly in MS [17]. To determine which medi-
cations to include in our definitions we compiled a list
of antidepressants (N06A), anti-anxiolytics (N05B), anti-
psychotics (N05A), combination agents (N06C), and
mood-stabilizing agents including anticonvulsants
(N05AN01, N03AG01, N03AX09, N03AX12) avail-
able in Canada based on the Anatomic Therapeutic
Chemical Classification System [18]. A multidisciplinary
panel comprised of two pharmacists (CE, MM), a psych-
iatrist (SBP), a neuropsychologist (JDF), an epidemio-
logist (SW), and a neurologist (RAM) independently
reviewed this list and indicated whether each medica-
tion was used (i) for each of the mental comorbidities of
interest; (ii) other on-label uses including the specific
condition; and (iii) off-label uses, especially for MS. To
meet our goal of enhancing the specificity of case defini-
tions with prescription claims, we selected medications
considered to be moderately specific for the comorbid-
ities of interest (Additional file 1: Table S1), meaning
that the medication could not be used off-label for MS,
and could not be used on or off-label for conditions
other than mental comorbidities unless an ICD code
could easily exclude the condition (e.g. epilepsy).
We developed several case definitions for each comor-
bidity by varying the number of physician, hospital and
prescription claims required and the years of data required
to classify a person as affected. Using our validation co-
hort, we compared the classification of mental comorbid-
ity according to the administrative case definitions versus
diagnoses based on medical records review for the 1 to
5 year periods ending in fiscal year 2005/06. We report a
kappa (κ) statistic for agreement between administrative
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interval (CI) based on the normal approximation to the
binomial distribution. We interpreted κ as follows: slight
(0-0.20), fair (0.21-0.40), moderate (0.41-0.60), substantial
(0.61-0.80), and almost perfect agreement (0.81-1.0) [19].
Kappa indicates the proportion of agreement beyond
chance and is calculated as (observed agreement – chance
agreement) ÷ (1 – chance agreement). Kappa is affected
by the prevalence of the condition of interest, however,
such that if prevalence is very high or very low, chance
agreement is high and kappa is reduced with a maximum
value of less than one [20]. Bias refers to the extent to
which the raters (i.e. administrative data versus medical
records data) disagree on the proportion of positive
(affected) cases; greater bias, meaning a greater differ-
ence in the proportion (prevalence) of positive rates, is
paradoxically associated with higher kappas. Because
both prevalence and bias influence the magnitude of
kappa, we also calculated the prevalence index, bias
index, and the prevalence and bias-adjusted kappa for
our preferred case definitions [20]. We estimated that a
sample of 400 persons can detect a k of ≥0.60 (substan-
tial agreement) for comorbidities with ≥4% prevalence if
the null hypothesis is k = 0.41, α = 0.05, and β = 0.20.
Given the anticipated higher k (≥ 0.70) for bipolar dis-
order and schizophrenia we estimated that our sample
would provide adequate precision for estimates of k
with prevalences ≥ 3% for these disorders.
We computed sensitivity, specificity, positive predict-
ive value (PPV) and negative predictive value (NPV) for
administrative definitions versus the “gold standard” of
medical records review to identify whether an algorithm
would be vulnerable to over- or under-estimating the
prevalence of the comorbidity. Further, we explored the
impact of these misclassifications on epidemiologic esti-
mates by generating a range of ‘true’ prevalence esti-
mates, and calculating the expected value of observed
prevalence based on the sensitivity and specificity for the
case definition of interest [7,21].
Prevalence
For each comorbidity, we report the prevalence in the
MS and matched cohorts. Once a person met the case
definition, he or she was considered affected in all subse-
quent years while alive and resident in Manitoba. We
estimated the point prevalence of the comorbidity on
October 1, 2005 using mid-year population figures for
denominators and also calculated prevalence ratios (PR)
by dividing the prevalence in those with MS by that of
the control group. To enhance comparability with other
study populations, we age-standardized the findings to
the 2001 Canadian population, and calculated 95% CIs
using the exact binomial distribution. Using Poisson re-
gression we calculated PRs and 95% CIs comparing theMS and general populations adjusting for age group
(20-44, 45-59, ≥ 60 years) and sex. Cell sizes ≤ 5 were
suppressed.
The University of Manitoba Health Research Ethics
Board and the Manitoba Health Information Privacy
Committee approved the study and data access. Partici-
pants in the validation cohort provided written informed
consent. Statistical analyses were performed using SAS
V9.2 (SAS Institute Inc., Cary NC).
Results
The MS population included 4192 persons and the
matched cohort included 20,940 persons (71.7% female).
In the validation cohort most participants were White
(91.6%), women (77.0%), with a mean (standard deviation)
age at MS symptom onset of 33.2 (11.1) years [16]. Mental
comorbidity was common in the validation cohort, with
29.7% having any mental comorbidity, 29.2% having a
mood or anxiety disorder, 27.5% having a depressive dis-
order, 6.5% having an anxiety disorder, 0.98% having bipo-
lar disorder and 0.49% having schizophrenia.
Omnibus definition: any mental comorbidity
Agreement between the administrative case definitions
(labeled A to Z) and medical records ranged from slight to
moderate (k = 0.11 to 0.51, Additional file 2: Table S2).
The definition with the highest level of agreement
required ≥ 1 hospital or ≥ 5 physician claims or ≥ 1
physician claim and ≥ 4 prescription claims in 2 years (def-
inition ‘Q’, k = 0.51); it had a sensitivity of 63% and a specifi-
city of 86.8%. Using definition ‘Q’, the age-standardized
prevalence of any mental comorbidity in 2005 was 33.9%
(95% CI 32.0-35.9%) in the MS population and 21.9% (95%
CI: 21.2-22.6%) in the general population (PR 1.55; 95% CI:
1.36-1.76). In both populations, the peak prevalence oc-
curred in persons aged 45-59 years (Figure 1).
Any mood or anxiety disorder
Agreement between the case definitions (labeled A to Y)
and medical records ranged from slight to moderate
(k = 0.10 to 0.50, Additional file 3: Table S3). The
highest level of agreement (k = 0.50) was achieved by sev-
eral similar definitions, including definition ‘O’ (see below);
all used prescription claims. Using definition ‘O’, (≥ 1 hos-
pital or ≥ 5 physician or [≥ 1 physician AND ≥ 4 prescrip-
tion] claims) the age-standardized prevalence of any mood
or anxiety disorder in 2005 was 34.8% (95% CI 32.8-36.8%)
in the MS population and 22.0% (95% CI: 21.3-22.7%) in
the general population (PR 1.58; 95% CI: 1.39-1.80). The
similarity of the estimates of any mood or anxiety disorder
to those for any mental comorbidity reflects the predomin-
ance of mood and anxiety disorders. In both populations,




























































































































Figure 1 Age-specific prevalence of mental comorbidity in the MS (A) and general populations (B). Administrative case definitions used:
Omnibus ≥ 1 Hospital or ≥ 5 Physician OR (≥ 1 Physician AND ≥ 4 Prescription claims) in 2 years. Mood disorder ≥ 1 Hospital or ≥ 5 Physician
OR (≥ 1 Physician AND ≥ 4 Prescription) in 2 years. Depression ≥ 1 Hospital or ≥ 5 Physician OR (≥ 1 Physician AND ≥ 7 Prescription) in 2 years.
Anxiety ≥ 1 Hospital or ≥ 2 Physician OR (≥ 1 Physician AND ≥ 2 Prescription) in 2 years. Bipolar disorder ≥ 1 Hospital or ≥ 3 Physician OR
(≥ 1 Physician AND ≥ 3 Prescription) in 5 years. Schizophrenia ≥ 1 Hospital or ≥ 2 Physician in 2 years.
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Agreement between the case definitions (labeled A to Y,
Additional file 4: Table S4) and medical records ranged
from slight to moderate (k = 0.11 to 0.49). The highest level
of agreement for a definition which did not use prescription
claims was moderate (k = 0.44), and used ≥ 1 hospital
or ≥4 physician claims in 5 years. Among all case definitions
the highest level of agreement (k = 0.49) was achieved by
two similar definitions (‘G’ and ‘P’); both used prescription
claims. Using definition ‘P’, which required (≥ 1 hospital
or ≥ 5 physician claims) or (≥ 1 physician claim and ≥ 7
prescription claims) in 2 years, the age-standardized preva-
lence of depression in 2005 was 31.7% (95% CI 29.8-33.5%)
in the MS population and 20.5% (95% CI: 19.8-21.2%) inthe general population (PR 1.60; 95% CI: 1.41-1.82). In
both populations, the peak prevalence occurred in persons
aged 45-59 years (Figure 1).
Anxiety disorders
Agreement between the administrative case definitions and
medical records ranged from slight to fair (k = 0.02 to 0.23,
Additional file 5: Table S5). The highest level of agreement
for any definition was fair (definition ‘N’, k = 0.23), and
required (≥ 1 hospital or ≥ 2 physician claims) or (≥ 1
physician and ≥ 2 prescription claims) in 2 years. Using
definition ‘N’, the age-standardized prevalence of anxiety in
2005 was 35.6% (95% CI 33.7-37.7%) in the MS population
and 29.6% (95% CI: 28.8-30.5%) in the general population
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peak prevalence occurred in persons aged 45-59 years
(Figure 1).
Bipolar disorder
Agreement between the administrative case definitions
(labeled A to U) and medical records ranged from slight
to moderate (k = 0.20 to 0.42, Additional file 6: Table S6).
Several definitions had the highest sensitivity of 75%
with specificities of 97% or higher. Agreement for these
definitions varied slightly, but confidence intervals over-
lapped. Using definition ‘W’, which required (≥ 1 hos-
pital or ≥ 3 physician claims) or (≥ 1 physician and ≥ 3
prescription claims) in 5 years (k = 0.34), the age-
standardized prevalence of bipolar disorder in 2005 was
5.83% (95% CI: 5.01-6.65%) in the MS population and
3.45% (95% CI: 3.17-3.73%) in the general population
(PR 1.70; 95% CI: 1.55-1.87). Although the affected
number of individuals was small, the prevalence of bipo-
lar disorder was similar across age groups (Figure 1).
Schizophrenia
Agreement between all of the case definitions (labeled A to
O) and medical records ranged from substantial to perfect
(k = 0.67 to 1.0, Additional file 7: Table S7). Among case
definitions with perfect agreement, the simplest definition
with the highest sensitivity (100%) and specificity (99%)
required ≥ 1 hospital or ≥ 2 physician claims in 2 years
(definition ‘G’). Applying definition ‘G’, the age-standardized
prevalence of schizophrenia in 2005 was 0.93% (95% CI:
0.61-1.26%) in the MS population and 0.93% (0.78-1.09%)
in the general population (PR 0.95; 95% CI: 0.60-1.51). Al-
though the small number of individuals affected requires
cautious interpretation, the prevalence of schizophrenia
was similar across age groups (Figure 1).
Misclassification bias
Table 1 shows the sensitivity, specificity, kappa, prevalence
index and bias index for case definitions for which we pre-
sented prevalence estimates. The definitions for bipolar
disorder, anxiety and schizophrenia have high values for
the prevalence index indicating that kappa values will be
reduced as compared to populations in which these condi-
tions are more prevalent. Except for anxiety, the bias index
was minimal. After adjustment for prevalence and bias, all
κ increased except for schizophrenia which was already
1.0. Graphical analysis of misclassification bias suggested
that the case definitions perform reasonably well in the
expected range of prevalence for mental comorbidity in
MS (Additional file 8: Figure S1) [1,2,22-28].
Discussion
Few population-based studies have evaluated the preva-
lence of mental comorbidity in MS [4]. To facilitate suchstudies, we validated case definitions for mental comorbid-
ities based on hospital, physician and prescription claims.
Our case definitions showed almost perfect agreement
versus medical records for schizophrenia, and moderate
agreement for any mental comorbidity, any mood or anx-
iety disorder, and depression. The case definition for bipo-
lar disorder had lower agreement, but acceptable sensitivity
of 75% and high specificity of 97.5%. The case definition
for anxiety had the lowest agreement but a specificity of
82%. Further, persons with MS were at increased risk of
depression, anxiety and bipolar disorder, but not schizo-
phrenia when compared to the general population.
Previous validation studies of administrative case defini-
tions for mental comorbidity were often disappointing, and
have highlighted the challenges of distinguishing depres-
sion from anxiety when using 3-digit ICD codes [11,12]. In
a Manitoba study, agreement was only fair (k = 0.26) be-
tween surveys and administrative definitions for depression
which used hospital, physician and prescription claims [11]
although this lower agreement may reflected their use
of survey data and a broader range of prescription claims
than in our study. Among persons newly treated with anti-
depressants in Saskatchewan, Canada, agreement between
depression identified on physician claims and medical
records was moderate (k = 0.54), similar to our findings
[29]. We could not identify any published, validated case
definitions for anxiety. Thus these validated case defini-
tions augment the ability to conduct population-level sur-
veillance of depression and anxiety. Despite challenges in
developing case definitions for depressive and anxiety dis-
orders sensitive and specific definitions were available for
bipolar disorder (sensitivity 75%, specificity 97%). Among
225 Americans, inpatient diagnoses of bipolar disorder,
outpatient diagnoses of bipolar disorder by mental health
providers, and outpatient diagnoses of bipolar disorder by
non-mental health providers that were accompanied by a
prescription for lithium, carbamazepine or valproate, had
false positive rates below 10% [30]. However, we found that
bipolar disorder could be identified without such claims.
Consistently, administrative case definitions for schizo-
phrenia have performed well, with agreement between
hospital claims for schizophrenia and medical records
of 93.9-100% [31,32]. In American Medicaid data, the
case definition that we validated of either one hospital
or two physician claims for schizophrenia in two years
identified only 6% false positives (k = 0.76) [33].Collect-
ively, this suggests that administrative data can accur-
ately identify bipolar disorder and schizophrenia in the
MS and general populations.
Our approach is informative for researchers wishing
to study mental comorbidity in other chronic neurologic
diseases, which share the potential problem of under-
reporting of comorbidities due to coding biases [34].
While prescription claims may add sensitivity, their use
Table 1 Impact of prevalence and bias on agreement (kappa) between administrative case definitions and medical
records
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2 ≥ 1 H or ≥ 5 P OR
(≥ 1 P AND ≥ 4 Rx)
63.5 (54.0, 72.2) 86.8 (82.1, 90.6) 0.51 (0.41, 0.60) 0.42 0.01 0.60
Any Mood or
anxiety disorder
2 ≥ 1 H or ≥ 5 P OR
(≥ 1 P AND ≥ 4 Rx)
62.8 (53.2, 71.7) 86.9 (82.2, 90.6) 0.50 (0.41, 0.60) 0.43 0.01 0.60
Depression 2 ≥ 1 H or ≥ 5 P OR
(≥ 1 P AND ≥ 7 Rx)
62.2 (52.4, 71.2) 86.7 (82.2, 90.4) 0.49 (0.40, 0.59) 0.45 0 0.60
Bipolar disorder 5 ≥ 1 H or ≥ 3P OR
(≥ 1 P AND ≥ 3 Rx)
75.0 (19.4, 99.4) 97.5 (95.5, 99.4) 0.30 (0.036, 0.57) 0.95 0.02 0.94
Anxiety 2 ≥ 1 H or ≥ 2 P OR
(≥ 1 P AND ≥ 2 Rx)
42.3 (23.3, 63.1) 82.2 (78.0, 85.9) 0.23 (0.022, 0.23) 0.74 0.12 0.69
Schizophrenia 2 ≥ 1 H or ≥ 2 P 1.0 (15.8, 100) 0.99 (98.6, 100) 1.0 (0, 1.0) 0.99 0 1.0
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logic diseases because of the frequent off-label use of
therapies. By restricting the breadth of prescriptions
used, and using them in combination with a physician
claim for mental comorbidity we successfully created
valid case definitions.
Prior studies suggest that the annual prevalence of de-
pression in MS is up to 14% with a lifetime prevalence of
up to 50% [1], and that anxiety disorders affect more than
30% of persons with MS [2,22]. Our crude prevalence esti-
mates of 33% for depression and 37% for anxiety based on
two years of administrative data are consistent with those
observations. The age-standardized prevalence of bipolar
disorder in the MS population was 5.83% (crude preva-
lence 6.3%), 70% higher than in the general population.
Studies in hospital or clinic populations suggested that bi-
polar disorder affects 0.30% to 13% of the MS population
[24-28]. The only one of these studies that used a true
general population control group reported that hospita-
lized persons with MS had bipolar disorder twice as often
as hospitalized controls (1.97% vs. 0.92%) [25]. Since that
study was limited to hospitalized persons, the prevalence
of bipolar disorder may have been underestimated, al-
though the increased risk of bipolar disorder in MS was
similar to our findings.
The prevalence of schizophrenia was the same in the
MS and general populations (0.93%). Two population-
based studies, both using administrative data, evaluated
the prevalence of psychosis, not limited to schizophrenia.
In Taiwan, psychosis affected 7.5% of the MS population
and 2.0% of the general population (odds ratio 4.0) [35].
In Alberta, Canada only 0.8% of MS patients had non-
organic pyschoses including schizophrenia-spectrum dis-
orders, and other non-organic psychoses, but this was
more than in the general population [4]. Our findings of
an absence of an increased prevalence of schizophrenia in
our MS population suggest a lack of increased risk whichmay reflect differences in the psychotic disorders studied
(all versus schizophrenia alone), as well as the small num-
ber of persons with schizophrenia.
Medical records review for the validation cohort did
not involve all records of all health care providers over
the lifetime of study participants. For practical reasons
we also compared medical records to administrative data
for the 1 to 5 year period ending in fiscal year 2005/06,
rather than from 1984 onward. Both factors may have
reduced agreement between the data sources. Like med-
ical records, administrative data only allow us to identify
mental comorbidities for which the patient has been
treated; undiagnosed mental comorbidity cannot be
captured without a direct patient assessment. This study
had several strengths, however. We validated the case
definitions in a population similar to the one in which it
was applied, the design was population-based, we used
matched general population controls, and we used mul-
tiple types of administrative data.
Conclusions
Our findings suggest that administrative data can be
used for surveillance for mental comorbidities in MS,
and should facilitate studies of the impact of mental
comorbidity on health outcomes captured by administrative
data such as health care utilization. Our findings also pro-
vide population-based data emphasizing the increased
prevalence of a range of mood and anxiety disorders in MS.
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